Peptide Companion
Peptide Companion
blend
Growth Hormone
Vial: 10 mg

How is CJC-1295 + GHRP-2 (10 mg Blend) dosed and mixed?

CJC-1295 + GHRP-2 (10 mg Blend) is a peptide blend research reference in the Growth Hormone category for a 10 mg vial. The reference mixing guide adds 3 mL of bacteriostatic water, giving a concentration of 3.33 mg/mL. The published research schedule lists 0.1–0.3 mg per injection, 2–3 times daily for 8–12 weeks; it is reference information, not a recommendation.

By Vincent Ceniceros · Published · Last updated

CJC-1295 is a long-acting GHRH analog that can elevate GH levels 2–10× baseline for approximately 6 days and increase IGF-1 by 1.5–3× for 9–11 days. GHRP-2 is a ghrelin-mimetic secretagogue with a plasma half-life of ~30 minutes that triggers rapid GH pulses peaking within ~25 minutes of administration. Combining these peptides leverages GHRP-2’s acute pulsatile release with CJC-1295’s sustained action. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

Dose
0.1–0.3 mg per injection
Frequency
2–3 times daily
Timing
Morning, post-workout, before bed
Duration
8–12 weeks

Moderate ghrelin activity. Increases appetite. Strong GH release.

Dosing Schedule
WeekDaily Dose (mcg)Units (per injection) (mL)
Weeks 1–2150 mcg (0.15 mg)4.5 units (0.045 mL)
Weeks 3–12300 mcg (0.30 mg)9 units (0.09 mL)
Mixing & Quick Reference
Bacteriostatic water
3 mL
Concentration
3.33 mg/mL
  • •Reconstitute: Add 3.0 mL bacteriostatic water → ~ 3.33 mg/mL concentration (1 unit ≈ 33.3 mcg).
  • •Typical daily range: 100–300 mcg once daily (gradual titration).
  • •Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
  • •Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F) for long-term; after reconstitution, refrigerate and use within 2–4 weeks.
Supplies Needed
  • •Peptide Vials (CJC-1295 + GHRP-2, 10 mg each):
  • •Insulin Syringes (U-100):
  • •Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • •Alcohol Swabs: One for the vial stopper + one for the injection site each day.
Benefits
  • •Sustained elevation of GH and IGF-1 levels over extended periods with once-daily or even less frequent dosing.
  • •Long-term pediatric studies (8 months) reported no significant adverse effects or toxicities from GHRP-2 therapy.
  • •GHRP-2 may transiently increase appetite due to ghrelin-like activity.
  • •Mild, transient elevations in ACTH, cortisol, and prolactin may occur shortly after injection but remain within physiological ranges.
  • •CJC-1295 at higher doses may cause transient vasodilatory effects such as facial flushing or brief lightheadedness.
  • •Occasional mild injection-site reactions (redness, itching) may occur with subcutaneous administration.
How It Works

CJC-1295 is a tetrasubstituted GHRH(1–29) analog engineered for extended half-life (~6–8 days) via protection from enzymatic degradation and reversible albumin binding. A single dose can sustain elevated GH for approximately 6 days and IGF-1 elevation for 9–11 days. GHRP-2 is a synthetic hexapeptide ghrelin-mimetic that binds the GH secretagogue receptor (GHS-R1a), triggering acute GH pulses that peak within ~25 minutes. Combining CJC-1295’s sustained GHRH signaling with GHRP-2’s rapid secretagogue action produces synergistic GH release that exceeds either peptide alone.

References and original studies

  • J Clin Endocrinol Metab (2006)

    Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting GHRH analog, in healthy adults

    View original study

  • J Clin Endocrinol Metab (1998)

    Mericq V et al. Effects of eight months treatment with graded doses of GHRP in GH-deficient children

    View original study

  • J Clin Endocrinol Metab (1998)

    Pihoker C et al. Pharmacokinetics and pharmacodynamics of GHRP-2: a phase I study in children

    View original study

  • J Clin Endocrinol Metab (2005)

    Laferrère B et al. GHRP-2, like ghrelin, increases food intake in healthy men

    View original study

  • Peptides (1997)

    Arvat E et al. Effects of GHRP-2 and hexarelin on GH, prolactin, ACTH, and cortisol levels in man

    View original study

  • WADA Technical Document (2019)

    Testing guide for Growth Hormone Releasing Factors (GHRFs), Version 2.0

    View source

  • CDC

    Vaccine administration: subcutaneous route (angle/site; no aspiration)

    View source

  • CDC (Subcut Injection PDF)

    Technique diagram and site guidance for subcutaneous injections

    View source

  • Bachem Technical Bulletin

    Handling and storage guidelines for peptides

    View source

  • NCBI Bookshelf

    Best practices for injection (asepsis, preparation, and administration)

    View original study

  • Subcutaneous Drug Injection Review (PMC)

    Pharmacologic considerations of the subcutaneous route

    View original study

About the author

Vincent Ceniceros

Vincent Ceniceros created Peptide Companion and publishes its Dosage Library. Each guide summarizes a reference protocol and links to the studies and sources it draws on.

Published · Last updated

Related guides

Work out the mixing math for any vial with the peptide reconstitution calculator, or browse the full Dosage Library.

Educational content adapted from peptidedosages.com. Not medical advice.